On April 22nd, Gelong Exchange (Conoya-B (2162.HK)) rose 6.12% to HK $23.4, with a total market capitalization of HK $6.5 billion. Conoya-B announced on the 19th that its new drug CMG901 (Claudin 18.2 antibody coupling drug) for the treatment of recurrent / refractory gastric cancer and gastroesophageal junction adenocarcinoma has recently been granted Fast track qualification (FTD) by the U.S. Food and Drug Administration (FDA). Previously, the company was approved by FDA for CMG901's clinical trial of gastric cancer and gastroesophageal junction adenocarcinoma in the United States in March last year and qualified as an orphan drug by FDA in April 2022.